TruAlt Bioenergy Ltd
TRUALTTruAlt Bioenergy Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 29% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (3 weeks in) while the P/E sits at the 56th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +1,080.0% year on year, and 29% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
TruAlt Bioenergy Ltd trades at ₹416, in a downtrend and 3 weeks into that stage. That is −7.8% against its own 200-day average. It sits at 46% of a 52-week range of ₹320 to ₹532. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (10 weeks and counting).
Today the stock is in a downtrend — week 3 of stage 4, confirmed. At ₹416 it trades −7.8% versus its 200-day average and sits at 46% of its 52-week range (₹320–₹532).
Against the market, two honest reads. Cumulative: over the last 11 months the stock moved −22% while the NIFTY 500 moved −1% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (10 weeks and counting; last ahead the week of 2026-07-03) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
TruAlt Bioenergy Ltd trades at 22.8× P/E, mid-range by its own standards (56th percentile). Its long-run median P/E is 21.6×, measured across 0.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.8× is mid-range by its own standards (56th percentile), against a long-run median of 21.6× measured over 0.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −46.1% against a −21.6% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, TruAlt Bioenergy Ltd was paying for profit growth of about 26.2% a year. Profit itself has compounded 40.5% a year over the past 3 years. Today the market pays 22.8× P/E, the 56th percentile of its own 1-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
TruAlt Bioenergy Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −9.4% | +31.4% | — | — |
| Profit | −34.0% | +40.5% | — | — |
| EPS | −46.1% | +24.4% | — | — |
| Share price | −21.6% | — | — | — |
4-Factor Sector Score
40.3/100 — rank 21 of 36 in Miscellaneous · 63% evidence confidence
TruAlt Bioenergy Ltd scores 40.3 out of 100 against the 36 companies it is compared with in Miscellaneous, ranking 21. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 10.7 + 9.3 + 10.3 + 10 = 40.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
TruAlt Bioenergy Ltd reported ₹627 Cr of revenue in the Jun 26 quarter, +106.3% year on year. Over 3 years it has compounded at 31.4% a year. The last full year, FY26, came in at ₹1,728 Cr. The last four reported quarters add to ₹2,051 Cr.
FY26 revenue came in at ₹1,728 Cr (−9.4% on the year), capping 3 years at 31.4% compound. The latest quarter (Jun 26) printed ₹627 Cr, +106.3% year on year.
Pace check: the last four quarters averaged +18.3% growth against the decade's 31.4% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
TruAlt Bioenergy Ltd's operating margin is 21.0% in the Jun 26 quarter, +7.0 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 14.0% to 17.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 21.0%, +7.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 14.0%–17.0%.
Why the margin moved: operating margin went +7.5 pp year on year while gross margin went +9.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
TruAlt Bioenergy Ltd earned ₹59.0 Cr of net profit in the Jun 26 quarter, +1,080.0% year on year. Full-year FY26 profit was ₹97.0 Cr. The 3-year compound rate is 40.5%. That is 9.4% of the quarter's revenue. The same quarter a year earlier earned ₹5.0 Cr. 3 of the last 9 reported quarters were loss-making.
Jun 26 profit was ₹59.0 Cr, +1,080.0% year on year. On the full year, FY26 printed ₹97.0 Cr (−34.0%), and the 3-year compound rate is 40.5%.
Why profit moved: revenue contributed +106.3% and the margin +7.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +344.5% vs revenue +18.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 29% of TruAlt Bioenergy Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−296 Cr of operating cash against ₹97.0 Cr of profit. After ₹510 Cr of capital spending, ₹−806 Cr was left as free cash.
FY26: operating cash of ₹−296 Cr against reported profit of ₹97.0 Cr, leaving free cash of ₹−806 Cr after ₹510 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 29% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 29%: the cash cycle stretched 242 days between FY23 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 242 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
TruAlt Bioenergy Ltd's cash conversion cycle runs 170 days in FY26, up from −72 days in FY23. Capital spending ran ₹1,151 Cr over the last 3 years. At FY26 sales of ₹1,728 Cr each day of that cycle holds about ₹4.7 Cr, so roughly ₹805 Cr sits inside the business at any moment.
FY26: debtors at 86 days, inventory at 173 days — roughly 5.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 170 days, looser than FY23's −72.
The full loop: cash goes out to suppliers and production on day 0; stock waits 173 days to sell; customers pay about 86 days after that; and suppliers themselves are paid at 89 days — netting out to the 170-day cycle.
In money terms: at FY26 sales of ₹1,728 Cr, each day of the cycle holds about ₹4.7 Cr — so the 170-day loop keeps roughly ₹805 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,151 Cr over the last 3 fiscal years against ₹210 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹68.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
TruAlt Bioenergy Ltd earns a ROCE of 10% in FY26. Return on invested capital clears the cost of that capital by −5.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 5.6% net margin on 0.46× asset turns.
FY26 ROCE is 10%.
🚨 Why the return is what it is — the wiring (FY26): 5.6% net margin × 0.46× asset turns × 2.48× balance-sheet leverage ≈ 6.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 6.9% − 12.0% = a −5.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
TruAlt Bioenergy Ltd carries total debt of ₹1,652 Cr against shareholder equity of ₹1,578 Cr as of Mar 26, a debt-to-equity of 1.05. On the annual view that ratio went from 2.02 in FY25 to 1.05 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹1,652 Cr against shareholder equity of ₹1,578 Cr — a debt-to-equity of 1.05. On the annual view, debt-to-equity went from 2.02 (FY25) to 1.05 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of TruAlt Bioenergy Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
TruAlt Bioenergy Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Gulshan Polyols LtdGULPOLY | 70.7/100Favorable setup87% evidence | ASLEEP | 27.5/35 Revenue 9.4% · PAT 100% · OPM change 7 pp 95% evidence | 19.2/25 ROCE 18.6% · OPM 13% 95% evidence | 13.2/20 P/E 7.4× · PEG — 50% evidence | 10.8/20 RS sector 3.7% · RS bench 7% · 1Y 8.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 27.5 + 19.2 + 13.2 + 10.8 = 70.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sagility LtdSAGILITY | 67.6/100Favorable setup87% evidence | TURNING | 24.7/35 Revenue 29.4% · PAT 49.3% · OPM change 0 pp 100% evidence | 15.8/25 ROCE 13.4% · OPM 22% 100% evidence | 13.5/20 P/E 20.6× · PEG 1.08 65% evidence | 13.6/20 RS sector 7.2% · RS bench 1.7% · 1Y 5.3%3 of 10 weeks ahead 70% evidence |
| Exact sum: 24.7 + 15.8 + 13.5 + 13.6 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3IIRM Holdings India Ltd526530 | 64.2/100Mixed-positive evidence75% evidence | LEADER | 16.3/35 Revenue 14.9% · PAT 12.7% · OPM change 1.1 pp 95% evidence | 19.0/25 ROCE 20.4% · OPM 24.6% 76% evidence | 9.9/20 P/E 39.9× · PEG — 15% evidence | 19.0/20 RS sector 42.8% · RS bench 47.3% · 1Y 79.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 19 + 9.9 + 19 = 64.2 · Decision use: Price leads the evidence: RS versus the benchmark is 47.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Exhicon Events Media Solutions Ltd543895 | 63.7/100Thin evidence · provisional60% evidence | TURNING | 19.0/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 20.1/25 ROCE 29.5% · OPM 28% 76% evidence | 13.4/20 P/E 19.2× · PEG — 50% evidence | 11.2/20 RS sector 2.2% · RS bench -1.9% · 1Y -4.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 19 + 20.1 + 13.4 + 11.2 = 63.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Aeroflex Enterprises LtdAEROENTER | 62.8/100Mixed-positive evidence87% evidence | LEADER | 19.7/35 Revenue 27.5% · PAT 100% · OPM change -5 pp 95% evidence | 14.9/25 ROCE 12.6% · OPM 9% 95% evidence | 9.0/20 P/E 10.2× · PEG — 50% evidence | 19.2/20 RS sector 38.8% · RS bench 42.9% · 1Y 57.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 14.9 + 9 + 19.2 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Global Education LtdGLOBAL | 62.5/100Mixed-positive evidence80% evidence | TURNING | 14.2/35 Revenue 28.2% · PAT 3.3% · OPM change 0.3 pp 95% evidence | 19.8/25 ROCE 29.2% · OPM 41% 95% evidence | 10.1/20 P/E 24.8× · PEG — 15% evidence | 18.4/20 RS sector 32.4% · RS bench 36.9% · 1Y 97.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 19.8 + 10.1 + 18.4 = 62.5 · Decision use: Price leads the evidence: RS versus the benchmark is 36.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Take Solutions LtdTAKE | 58.7/100Thin evidence · provisional57% evidence | 24.7/35 Revenue — · PAT 100% · OPM change 2932.2 pp 57% evidence | 8.5/25 ROCE 11.2% · OPM — 80% evidence | 8.5/20 P/E 3222× · PEG — 15% evidence | 17.0/20 RS sector 71.1% · RS bench 71.4% · 1Y 300.4%11 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 24.7 + 8.5 + 8.5 + 17 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8R K Swamy LtdRKSWAMY | 57.1/100Mixed-positive evidence65% evidence | 22.5/35 Revenue 14.3% · PAT 17.3% · OPM change 2.6 pp 95% evidence | 15.6/25 ROCE 12.3% · OPM 10.4% 95% evidence | 10.7/20 P/E 19.5× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -16.7% · 1Y —4 of 5 weeks ahead to 2026-08-16 25% evidence | |
| Exact sum: 22.5 + 15.6 + 10.7 + 8.3 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Aegis Vopak Terminals LtdAEGISVOPAK | 55.8/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.9/35 Revenue 25.9% · PAT 40.9% · OPM change 2 pp 95% evidence | 13.2/25 ROCE 7.6% · OPM 77% 76% evidence | 8.9/20 P/E 121× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 25.5% · 1Y 24.5%10 of 10 weeks ahead 25% evidence |
| Exact sum: 21.9 + 13.2 + 8.9 + 11.8 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Parin Enterprises LtdPARIN | 52.2/100Mixed-positive evidence63% evidence | FADING | 19.4/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 11.6/25 ROCE 10.8% · OPM 9% 95% evidence | 9.1/20 P/E 117× · PEG — 15% evidence | 12.1/20 RS sector 5.1% · RS bench 8.7% · 1Y 46.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 11.6 + 9.1 + 12.1 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Eveready Industries India LtdEVEREADY | 50.9/100Mixed-positive evidence94% evidence | TURNING | 18.9/35 Revenue 8.7% · PAT 100% · OPM change 1 pp 100% evidence | 13.6/25 ROCE 17.2% · OPM 15% 100% evidence | 9.0/20 P/E 16.6× · PEG 2.1 100% evidence | 9.4/20 RS sector -9.5% · RS bench 8.6% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 18.9 + 13.6 + 9 + 9.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GMR Airports LtdGMRAIRPORT | 50.8/100Mixed-positive evidence74% evidence | ASLEEP | 22.7/35 Revenue 38.8% · PAT 100% · OPM change 1 pp 74% evidence | 11.3/25 ROCE 11.6% · OPM 37% 100% evidence | 8.7/20 P/E 184× · PEG — 15% evidence | 8.1/20 RS sector -2.8% · RS bench 0.5% · 1Y 14%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.7 + 11.3 + 8.7 + 8.1 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Anzen India Energy Yield Plus TrustANZEN | 50.3/100Mixed-positive evidence60% evidence | TURNING | 20.7/35 Revenue 100% · PAT 100% · OPM change -9 pp 95% evidence | 9.1/25 ROCE 3.3% · OPM 80% 76% evidence | 9.3/20 P/E 99.7× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 7.3% · 1Y 8.7%1 of 10 weeks ahead 25% evidence |
| Exact sum: 20.7 + 9.1 + 9.3 + 11.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Jai Corp LtdJAICORPLTD | 48.3/100Mixed-negative evidence74% evidence | BASING | 19.6/35 Revenue 2.7% · PAT -40.4% · OPM change 9 pp 95% evidence | 11.4/25 ROCE 11.8% · OPM 15% 95% evidence | 10.9/20 P/E 17.8× · PEG — 15% evidence | 6.4/20 RS sector -8.2% · RS bench -19.2% · 1Y -40.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 19.6 + 11.4 + 10.9 + 6.4 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Inox Green Energy Services LtdINOXGREEN | 48.0/100Mixed-negative evidence75% evidence | ASLEEP | 22.2/35 Revenue 16.5% · PAT 100% · OPM change -13.2 pp 95% evidence | 9.1/25 ROCE 8.4% · OPM -2.2% 76% evidence | 9.7/20 P/E 58.4× · PEG — 15% evidence | 7.0/20 RS sector -6% · RS bench -2.9% · 1Y 19.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 9.1 + 9.7 + 7 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16TCC Concept LtdTCC | 47.5/100Mixed-negative evidence81% evidence | BASING | 16.6/35 Revenue 100% · PAT 51.1% · OPM change -45 pp 95% evidence | 11.8/25 ROCE 5.7% · OPM 36% 95% evidence | 14.1/20 P/E 20× · PEG — 50% evidence | 5.0/20 RS sector -17.6% · RS bench -31.9% · 1Y -89.7%0 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.8 + 14.1 + 5 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Prozone Realty LtdPROZONER | 46.4/100Mixed-negative evidence80% evidence | TURNING | 17.0/35 Revenue -9.9% · PAT 100% · OPM change 8.2 pp 95% evidence | 6.4/25 ROCE -1% · OPM -35.6% 95% evidence | 9.6/20 P/E 62.1× · PEG — 15% evidence | 13.4/20 RS sector -0.3% · RS bench 3.1% · 1Y 21.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.4 + 9.6 + 13.4 = 46.4 · Decision use: Price leads the evidence: RS versus the benchmark is 3.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Aqylon Nexus LtdAQYLON | 45.9/100Mixed-negative evidence72% evidence | BASING | 18.5/35 Revenue 100% · PAT 100% · OPM change 2358 pp 71% evidence | 18.8/25 ROCE 131% · OPM 58% 95% evidence | 8.6/20 P/E 759× · PEG — 15% evidence | 0.0/20 RS sector -76.3% · RS bench -75.3% · 1Y -79.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 18.8 + 8.6 + 0 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jindal Photo LtdJINDALPHOT | 43.3/100Mixed-negative evidence77% evidence | ASLEEP | 20.4/35 Revenue 100% · PAT -80% · OPM change 15 pp 95% evidence | 10.1/25 ROCE -1.4% · OPM 98% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -19.1% · RS bench -16.2% · 1Y -14.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 10.1 + 10 + 2.8 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Shipping Corporation of India Land & Assets LtdSCILAL | 42.8/100Mixed-negative evidence80% evidence | BASING | 24.2/35 Revenue 23.8% · PAT 100% · OPM change 13 pp 95% evidence | 5.0/25 ROCE 1.3% · OPM -14% 95% evidence | 9.5/20 P/E 62.3× · PEG — 15% evidence | 4.1/20 RS sector -17.6% · RS bench -14.8% · 1Y -26.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 5 + 9.5 + 4.1 = 42.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -17.6% and the one-year return is -26.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 21TruAlt Bioenergy Ltdthis pageTRUALT | 40.3/100Mixed-negative evidence63% evidence | ASLEEP | 10.7/35 Revenue 1.8% · PAT -8.1% · OPM change 7 pp 100% evidence | 9.3/25 ROCE 10.4% · OPM 21% 100% evidence | 10.3/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -21.6%2 of 12 weeks ahead 0% evidence |
| Exact sum: 10.7 + 9.3 + 10.3 + 10 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22GKW LtdGKWLIMITED | 39.2/100Mixed-negative evidence71% evidence | ASLEEP | 10.9/35 Revenue -13.5% · PAT 0% · OPM change -2 pp 95% evidence | 9.2/25 ROCE 0.5% · OPM 84% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.1/20 RS sector -0.9% · RS bench -4.5% · 1Y -9.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 10.9 + 9.2 + 10 + 9.1 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Unitech LtdUNITECH | 36.8/100Mixed-negative evidence69% evidence | BASING | 18.0/35 Revenue 45.3% · PAT -10% · OPM change 15 pp 71% evidence | 3.5/25 ROCE 0.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.3/20 RS sector -22.3% · RS bench -19.7% · 1Y -39.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 3.5 + 10 + 5.3 = 36.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Kaveri Seed Company LtdKSCL | 35.9/100Mixed-negative evidence94% evidence | BASING | 11.3/35 Revenue 1.4% · PAT -21.7% · OPM change 1 pp 100% evidence | 14.4/25 ROCE 18.8% · OPM 40% 100% evidence | 4.7/20 P/E 14.8× · PEG 3.12 100% evidence | 5.5/20 RS sector -17.2% · RS bench -19.8% · 1Y -40%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.3 + 14.4 + 4.7 + 5.5 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Delta Corp LtdDELTACORP | 35.4/100Mixed-negative evidence81% evidence | BASING | 9.7/35 Revenue -9.3% · PAT -80% · OPM change -3 pp 95% evidence | 8.6/25 ROCE 5.1% · OPM 18% 95% evidence | 12.0/20 P/E 9.4× · PEG — 50% evidence | 5.1/20 RS sector -18.1% · RS bench -18.3% · 1Y -36.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 9.7 + 8.6 + 12 + 5.1 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Stanley Lifestyles LtdSTANLEY | 30.0/100Adverse evidence74% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -80% · OPM change -3.4 pp 95% evidence | 10.8/25 ROCE 6.4% · OPM 17.3% 95% evidence | 9.2/20 P/E 112× · PEG — 15% evidence | 3.4/20 RS sector -43.7% · RS bench -25.2% · 1Y -54.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 10.8 + 9.2 + 3.4 = 30 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Embassy Developments LtdEMBDL | 26.2/100Adverse evidence64% evidence | BASING | 5.9/35 Revenue -46.6% · PAT -80% · OPM change -58.4 pp 71% evidence | 3.4/25 ROCE -2.4% · OPM -60% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.9/20 RS sector -18.4% · RS bench -15.8% · 1Y -42.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 5.9 + 3.4 + 10 + 6.9 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28RattanIndia Enterprises LtdRTNINDIA | 17.5/100Adverse evidence74% evidence | ASLEEP | 2.7/35 Revenue 2.1% · PAT -80% · OPM change -23.9 pp 100% evidence | 1.0/25 ROCE -4.8% · OPM 2.1% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -32.1% · RS bench -24.4% · 1Y -55.3%1 of 10 weeks ahead 70% evidence |
| Exact sum: 2.7 + 1 + 10 + 3.8 = 17.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Central Mine Planning & Design Institute LtdCMPDI | 63.2/100Thin evidence · provisional40% evidence | ASLEEP | 22.4/35 Revenue — · PAT — · OPM change 8 pp 34% evidence | 20.6/25 ROCE 38.1% · OPM 30% 100% evidence | 10.2/20 P/E 23.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence |
| Exact sum: 22.4 + 20.6 + 10.2 + 10 = 63.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30FlySBS Aviation LtdFLYSBS | 57.7/100Thin evidence · provisional41% evidence | BREAKING OUT | 15.4/35 Revenue — · PAT — · OPM change -8 pp 26% evidence | 19.4/25 ROCE 32.5% · OPM 21% 95% evidence | 10.6/20 P/E 20× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 43.9% · 1Y 14.1%6 of 10 weeks ahead 25% evidence |
| Exact sum: 15.4 + 19.4 + 10.6 + 12.3 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Qualitek Labs Ltd544091 | 54.3/100Thin evidence · provisional29% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -3 pp 7% evidence | 15.1/25 ROCE 11.9% · OPM 26% 76% evidence | 9.8/20 P/E 44.2× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 42.7% · 1Y —4 of 6 weeks ahead 25% evidence |
| Exact sum: 17.3 + 15.1 + 9.8 + 12.1 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Shree Vasu Logistics LtdSVLL | 52.6/100Thin evidence · provisional50% evidence | BREAKING OUT | 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 26% evidence | 16.0/25 ROCE 12.9% · OPM 25.8% 95% evidence | 8.8/20 P/E 126× · PEG — 15% evidence | 9.5/20 RS sector -16.1% · RS bench 17.5% · 1Y 2.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 18.3 + 16 + 8.8 + 9.5 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Indiqube Spaces LtdINDIQUBE | 49.7/100Thin evidence · provisional49% evidence | BREAKING OUT | 18.9/35 Revenue 38.9% · PAT 30.4% · OPM change 0 pp 71% evidence | 9.3/25 ROCE 6.4% · OPM 61% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.5/20 RS sector — · RS bench 10.4% · 1Y -11.8%5 of 10 weeks ahead 25% evidence |
| Exact sum: 18.9 + 9.3 + 10 + 11.5 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Maagh Advertising & Marketing Services Ltd543624 | 49.5/100Thin evidence · provisional35% evidence | 18.4/35 Revenue — · PAT — · OPM change 275.6 pp 32% evidence | 9.1/25 ROCE -0.4% · OPM 55.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.0/20 RS sector — · RS bench 37% · 1Y —7 of 9 weeks ahead to 2025-03-19 25% evidence | |
| Exact sum: 18.4 + 9.1 + 10 + 12 = 49.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Tandhan Industries Ltd512062 | 46.3/100Thin evidence · provisional33% evidence | BREAKING OUT | 20.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.7/25 ROCE -0.3% · OPM 15.8% 76% evidence | 9.4/20 P/E 71.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 10 weeks ahead 0% evidence |
| Exact sum: 20.2 + 6.7 + 9.4 + 10 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Shree Rama Newsprint LtdRAMANEWS | 45.4/100Thin evidence · provisional46% evidence | 14.1/35 Revenue -20% · PAT 69.8% · OPM change -8 pp 40% evidence | 6.1/25 ROCE 1.9% · OPM 8% 71% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.2/20 RS sector 9.7% · RS bench 10.5% · 1Y 21.7%11 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 14.1 + 6.1 + 10 + 15.2 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is TruAlt Bioenergy Ltd's share price today?
TruAlt Bioenergy Ltd trades at ₹416, −21.6% over the past year. The company is valued at ₹3,570 Cr. The stock sits at 46% of its 52-week range of ₹320–₹532, −7.8% versus its 200-day average. On the tape, the price is in a downtrend, 3 weeks in. — as of 11 September 2026.
What were TruAlt Bioenergy Ltd's latest quarterly results?
TruAlt Bioenergy Ltd reported revenue of ₹627 Cr and net profit of ₹59.0 Cr for the Jun 26 quarter. Revenue rose 106.3% and profit rose 1,080.0% year on year. Earnings per share were ₹6.66. The operating margin was 21.0%, 7.0 pp higher than a year earlier. — as of 11 September 2026.
What is TruAlt Bioenergy Ltd's revenue?
TruAlt Bioenergy Ltd reported revenue of ₹627 Cr in the Jun 26 quarter, +106.3% year on year. For the full FY26 fiscal year, revenue was ₹1,728 Cr (−9.4%). Over the last 3 years revenue compounded at 31.4% a year. — as of 11 September 2026.
What is TruAlt Bioenergy Ltd's profit?
TruAlt Bioenergy Ltd earned ₹59.0 Cr of net profit in the Jun 26 quarter, +1,080.0% year on year. Full-year FY26 profit was ₹97.0 Cr. The operating margin ran 21.0% in the latest quarter. — as of 11 September 2026.
What is TruAlt Bioenergy Ltd's market cap?
TruAlt Bioenergy Ltd's market capitalisation is ₹3,570 Cr at a share price of ₹416. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is TruAlt Bioenergy Ltd's P/E ratio?
TruAlt Bioenergy Ltd trades at a P/E of 22.8×, at the 56th percentile of its own 1-year range, against a long-run median of 21.6×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does TruAlt Bioenergy Ltd pay a dividend?
No — TruAlt Bioenergy Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is TruAlt Bioenergy Ltd overvalued?
On its own history, TruAlt Bioenergy Ltd looks mid-range: its P/E of 22.8× sits at the 56th percentile of its 1-year range (long-run median 21.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is TruAlt Bioenergy Ltd growing?
Yes — TruAlt Bioenergy Ltd is growing: latest-quarter revenue +106.3% year on year, profit +1,080.0%, and the margin +7.0 pp at 21.0%. The 3-year compound rates are 31.4% (revenue) and 40.5% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is TruAlt Bioenergy Ltd performing?
TruAlt Bioenergy Ltd is in a downtrend, 3 weeks in. Its latest quarter's revenue rose 106.3% and profit rose 1,080.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is TruAlt Bioenergy Ltd in an uptrend?
No — the price is in a downtrend (week 3 of stage 4), trading −7.8% versus its 200-day average and at 46% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is TruAlt Bioenergy Ltd beating the market?
Not lately — on a trailing-13-week view TruAlt Bioenergy Ltd is currently behind the NIFTY 500 (10 weeks and counting; last ahead the week of 2026-07-03), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 11 months the stock moved −22% against the NIFTY 500's −1% — behind the index over the full window. — as of 11 September 2026.
Will TruAlt Bioenergy Ltd's share price go up?
This page publishes no price forecast for TruAlt Bioenergy Ltd. What it measures instead: the share price is ₹416, the price is in a downtrend 3 weeks in. Its P/E of 22.8× sits at the 56th percentile of its own 1-year range. — as of 11 September 2026.
Who owns TruAlt Bioenergy Ltd?
Promoters hold 70.5% of TruAlt Bioenergy Ltd, foreign institutions 0.6%, domestic institutions 8.4% and the public 20.5% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does TruAlt Bioenergy Ltd have too much debt?
It carries real leverage — TruAlt Bioenergy Ltd's debt-to-equity is 1.09, and operating profit covers the interest bill 2×. FY26 borrowings were ₹1,652 Cr against equity of ₹1,521 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is TruAlt Bioenergy Ltd's capex?
TruAlt Bioenergy Ltd spent ₹1,151 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹510 Cr, with ₹68.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is TruAlt Bioenergy Ltd's cash flow?
TruAlt Bioenergy Ltd consumed ₹296 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−806 Cr). Operating cash was negative while the company reported a profit of ₹97.0 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is TruAlt Bioenergy Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 29% of TruAlt Bioenergy Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−296 Cr against reported profit of ₹97.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is TruAlt Bioenergy Ltd in its business cycle?
TruAlt Bioenergy Ltd's FY26 operating margin was 17.0%, against a 4-year band of 14.0%–17.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does TruAlt Bioenergy Ltd's price assume?
At its price on 13 June 2026, TruAlt Bioenergy Ltd was priced for profit growth of about 26.2% a year. Profit itself has compounded 40.5% a year over the past 3 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the TruAlt Bioenergy Ltd story?
The sharpest disagreement: profits are rising, but only 29% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is TruAlt Bioenergy Ltd a stock worth studying right now?
This is not investment advice. The machine read: TruAlt Bioenergy Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!